Infectious Disease Advisor news story
Adults with HIV aged 60 years and older are more likely to report favorable quality of life (QOL) following a switch in antiretroviral therapy (ART) than adults younger than 60 years, according to study findings published in HIV Medicine.
Older adults represent a growing proportion of people with HIV, but evidence regarding patient-reported outcomes among those aged 60 years and older remains limited.
Researchers assessed whether advanced age was associated with reasons for ART modification, QOL, and clinical outcomes among adults with HIV who switched to bictegravir-based 3-drug regimens (BIC 3DR) or dolutegravir-based 2-drug regimens (DTG 2DR). They performed a cross-sectional evaluation of prospectively gathered data from an ongoing cohort involving 11 hospitals in Spain that began enrollment in 2018. The analysis included adults with HIV aged 50 years and older who switched to BIC 3DR or DTG 2DR in routine clinical practice. Participants were grouped according to whether they were younger than 60 years or aged 60 years and older at the time of treatment modification.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
UCSF | How a new long-acting HIV drug combo tackles resistance
-
LSE | New study finds major HIV service declines in Uganda and Zimbabwe after 2025 US aid cuts
-
[Press release] ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.